Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 7/20 | 0.47 |
| ▸ | FNTB | P49356 | 7/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAT2A | P31153 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547648 | 0.91 | SRD5A2 (0.43) | FNTAFNTBSRD5A2CES2HPGD | |
| SCHEMBL26300565 | 0.84 | FNTA (0.47) | FNTAFNTBSRD5A2CNR2ADORA1 | |
| SCHEMBL30676989 | 0.84 | MAPT (0.43) | HPGDLMNAMAPT | |
| SCHEMBL26300513 | 0.82 | BACE1 (0.45) | FNTAFNTBSRD5A2CNR2CNR1 | |
| SCHEMBL29547634 | 0.82 | FNTA (0.54) | FNTAFNTBSRD5A2CES2MAPT | |
| SCHEMBL29547156 | 0.81 | L3MBTL1 (0.36) | FNTAFNTBHPGDLMNAMAPT | |
| SCHEMBL25399546 | 0.81 | BAZ2B (0.38) | HPGDMAT2AMAPT | |
| SCHEMBL26300393 | 0.80 | BACE1 (0.45) | FNTAFNTBSRD5A2CNR2MAT2A | |
| SCHEMBL25402450 | 0.79 | FNTA (0.68) | FNTAFNTBLMNAMAPT | |
| SCHEMBL29547188 | 0.79 | ALDH1A1 (0.40) | FNTAFNTBSRD5A2CES2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233864-B1 | COMPOSITION COMPRISING AN INDOLIZINE DERIVATIVE AND A CYCLIC DINUCLEOTIDE AS ACTIVE AGENTS | UNIV AJOU IND ACADEMIC COOP FOUND (KR) | 2025-02-12 | — | — | EP | disclosed |
| US-20230390319-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-12-07 | — | — | US | disclosed |
| EP-4233864-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | Ajou University Industry-Academic Cooperation Foundation (KR) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022086260-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | 아주대학교산학협력단 | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390319-A1 | INTERFERON GENE STIMULATOR COMPOSITION COMPRISING INDOLIZINE DERIVATIVE AS ACTIVE INGREDIENT | STING1, IRF3, IFNG | FNTA 2708/4885FNTB 2743/4885SRD5A2 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.